Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SSGJ 705

Next Previous
Drug Profile

SSGJ 705

Alternative Names: 705; SSGJ-705

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3SBio
  • Developer 3SBio; Sunshine Guojian Pharmaceutical
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Gastric cancer; Non-small cell lung cancer
  • Phase I Cancer

Most Recent Events

  • 30 Jul 2025 Phase-II clinical trials in Breast cancer (Second-line therapy or greater, Monotherapy, Late-stage disease, Metastatic disease) in China (Parenteral) (NCT07022002)
  • 30 Jul 2025 Phase-II clinical trials in Gastric cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in China (Parenteral) (NCT07022002)
  • 30 Jul 2025 Phase-II clinical trials in Gastric cancer (Monotherapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in China (Parenteral) (NCT07022002)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top